Self-assembled antibacterial peptide for resisting drug-resistant bacteria as well as preparation method and application of self-assembled antibacterial peptide

By designing and synthesizing self-assembled antimicrobial peptide 3RF, the amino acid sequence and disulfide bond connection of branched chain A and branched chain B are solved, and the problem of high toxicity and poor activity of self-assembled antimicrobial peptides is achieved, and the effectiveness of drug-resistant bacteria is achieved Inhibitory and low toxicity, with significant therapeutic potential.

CN118930607AActive Publication Date: 2024-11-12NORTHEAST AGRICULTURAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410971569.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-12
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

The existing self-assembled antimicrobial peptides have problems of high toxicity and poor activity against drug-resistant bacteria, and it is difficult to effectively inhibit drug-resistant bacterial infection.

Method used

Design a self-assembled antimicrobial peptide 3RF, driven by disulfide bond linkage and cation-π action between the amino acid sequences of branched chain A and branched chain B, synthesized by solid-phase chemical synthesis and identified by mass spectrometry and high-performance liquid chromatography purification to form a stable fiber-mounted structure with low toxicity and high-efficiency inhibition of drug-resistant bacteria.

Benefits of technology

Antimicrobial peptide 3RF has excellent inhibitory effects on methicillin-resistant Staphylococcus aureus, kanamycin-resistant E. coli and spectacular Pseudomonas aeruginosa, and has almost no toxicity to human red blood cells, which significantly improves the drug-resistant bacteria. Therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930607A_ABST
    Figure CN118930607A_ABST
Patent Text Reader

Abstract

The invention discloses a self-assembled antibacterial peptide for resisting drug-resistant bacteria as well as a preparation method and application of the self-assembled antibacterial peptide, and belongs to the technical field of biology. Comprising a branched chain A and a branched chain B, the amino acid sequence of the branched chain A is RRRCFFF, the amino acid sequence of the branched chain B is FFFCRRR, and the branched chain A and the branched chain B are connected through a disulfide bond formed between thiol groups in two cysteine residues. The antibacterial peptide 3RF disclosed by the invention is self-assembled into a nanofiber structure in a PB solution, has strong antibacterial activity on drug-resistant bacteria, almost has no hemolytic toxicity, and has extremely high application potential in the aspect of treating infection caused by the drug-resistant bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a self-assembling antimicrobial peptide for resisting drug-resistant bacteria, and a preparation method and application thereof. Background Art

[0002] Antimicrobial peptides (AMPs) are considered as an attractive and promising strategy to combat the terrible multidrug-resistant bacterial infections. Unlike traditional antibiotics that act on limited fixed targets, antimicrobial peptides mainly cause bacterial death by physically destroying the integrity of bacterial membranes. This antibacterial mechanism reduces the probability of bacterial resistance to antimicrobial peptides. Since the ordered nanostructure of self-assembled antimicrobial peptides helps to improve the activity and stability of antimicrobial peptides, thereby enhancing their activity against drug-resistant bacteria. In addition, self-assembled nano-delivery systems can alleviate the pharmacokinetic / pharmacodynamic defects of antimicrobial peptides, improve their shelf life, stability and bioavailability, and prolong the half-life of antimicrobial peptides. Therefore, self-assembled antimicrobial peptides have great potential in the treatment of bacterial infections, especially drug-resistant bacterial infections. However, most chemically modified self-assembled antimicrobial peptides have toxic effects that cannot be ignored, and self-assembled antimicrobial peptides driven by amino acid intermolecular forces often have weak activity, making them unable to become antibacterial agents against drug-resistant bacteria. Therefore, it is particularly necessary to develop non-toxic and highly effective antimicrobial peptides against drug-resistant bacteria. Summary of the invention

[0003] Based on the above shortcomings, the purpose of the present invention is to provide a self-assembling antimicrobial peptide 3RF for use against drug-resistant bacteria and a preparation method and application thereof, which solves the problems of high toxicity and poor activity against drug-resistant bacteria of existing self-assembling antimicrobial peptides, and has the ability to inhibit drug-resistant bacteria with low toxicity and high efficiency.

[0004] The technical solution adopted by the present invention is as follows: a self-assembling antimicrobial peptide 3RF for resisting drug-resistant bacteria, comprising branch A and branch B, the amino acid sequence of branch A is: RRRCFFF, the amino acid sequence of branch B is: FFFCRRR, and the branch A and branch B are connected by a disulfide bond formed between the thiol groups in two cysteine ​​residues.

[0005] Furthermore, the molecular formula of the antimicrobial peptide 3RF as described above is shown in formula (I):

[0006]

[0007] Furthermore, the antimicrobial peptide 3RF described above was dissolved in a PB buffer solution with a concentration of 10 mM and a pH of 7.4, wherein the concentration of the antimicrobial peptide 3RF was 32-256 μM, and incubated at room temperature for 12 hours to self-assemble into a nanostructure.

[0008] Another object of the present invention is to provide a method for preparing the self-assembling antimicrobial peptide 3RF for resisting drug-resistant bacteria as described above, as follows: design two branches, the sequence of branch A is: RRRCFFF, the sequence of branch B is: FFFCRRR, branch A and branch B are connected by a disulfide bond formed between thiol groups in two cysteine ​​residues, and self-assembly of branch A and branch B is driven by cation-π interaction; branch A and branch B are synthesized separately by solid phase chemical synthesis, and then branch A and branch B are connected by a disulfide bond formed between thiol groups in two cysteine ​​residues, the polypeptide is subjected to mass spectrometry identification and reversed-phase high performance liquid chromatography purification to obtain the polypeptide, and then the polypeptide self-assembly morphology is observed, antibacterial activity is determined, and hemolytic toxicity is determined, and finally named antimicrobial peptide 3RF.

[0009] Another object of the present invention is to provide the use of the self-assembling antimicrobial peptide 3RF against drug-resistant bacteria as described above in the preparation of a drug for treating infectious diseases caused by drug-resistant bacteria, wherein the drug-resistant bacteria are methicillin-resistant Staphylococcus aureus, kanamycin-resistant Escherichia coli or spectinomycin-resistant Pseudomonas aeruginosa.

[0010] The present invention has the following advantages and beneficial effects: the self-assembling antimicrobial peptide 3RF of the present invention can form a stable fiber-assembled structure, has an excellent inhibitory effect on drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus, kanamycin-resistant Escherichia coli and spectinomycin-resistant Pseudomonas aeruginosa, and has almost no toxicity to human red blood cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 is the mass spectrum of antimicrobial peptide 3RF;

[0012] Figure 2 is the HPLC chromatogram of the antimicrobial peptide 3RF;

[0013] Figure 3 It is the minimum aggregation concentration diagram (CAC) of antimicrobial peptide 3RF;

[0014] Figure 4 This is a graph showing the hemolytic activity of the antimicrobial peptide 3RF. DETAILED DESCRIPTION

[0015] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0016] Example 1

[0017] Design of antimicrobial peptides

[0018] Design principle: Two branches are designed, branch A, sequence: RRRCFFF, branch B, sequence: FFFCRRR, branch A and branch B are connected by a disulfide bond formed between the thiol groups in the two cysteine ​​residues, and the polypeptide sequence uses the cation-π effect (RF) to drive its self-assembly; then solid-phase chemical synthesis is used to synthesize branch A and branch B separately, and then branch A and branch B are connected by a disulfide bond formed between the thiol groups in the two cysteine ​​residues.

[0019] The amino acid sequence of the antimicrobial peptide 3RF is as follows:

[0020]

[0021] Table 1 Amino acid sequences of antimicrobial peptides

[0022]

[0023] The molecular formula of the self-assembling antimicrobial peptide 3RF is shown in formula (I),

[0024]

[0025] Example 2

[0026] 1. Synthesis of antimicrobial peptides by solid phase chemical synthesis

[0027] 1. First, connect Fmoc-Arg(pbf)-OH to Rink resin, then remove piperidine after 30 minutes of piperidine deprotection reaction, and wash with dimethylformamide (DMF), and detect the deprotection color with ninhydrin. Then connect the subsequent straight-chain amino acids in sequence until they are connected to Fmoc-Trp(boc)-OH at the N-terminus, and remove the Fmoc at the N-terminus to obtain FFFC(Trt)R(pbf)R(pbf)R(pbf). Cleave the monomer peptide from the resin with 95% TFA, and cut off all the side chain protecting groups of the sequence. Obtain the crude FFFC(Trt)R(pbf)R(pbf)R(pbf), liquid phase purification, and freeze-drying.

[0028] 2. Prepare R(pbf)R(pbf)R(pbf)C(Trt)FFF in the same way as step 1, cleave the monomer peptide from the resin, and cut off all the side chain protecting groups of the sequence. Obtain the crude product of R(pbf)R(pbf)R(pbf)C(Trt)FFF monomer, liquid phase purification, and freeze-drying.

[0029] 3. Oxidative synthesis: dissolve two monomer peptides, mix them, adjust the pH to 7.5-8 with ammonium bicarbonate solution, stir for 1 hour, monitor the oxidation status by mass spectrometry and liquid chromatography, and after complete oxidation, purify by HPLC, freeze-dry, and you can get the target product.

[0030] 2. Purification and Identification:

[0031] 1. Detection of crude product MS: Take a small amount of crude product, dissolve it and use LC-MS to determine the molecular weight (such as Figure 1 The molecular weight of the product was basically consistent with the theoretical molecular weight in Table 1 before purification.

[0032] 2. Purification: Use high performance liquid chromatography to purify the peptide to obtain a peptide with a purity of >95%; Figure 2 Shown is the HPLC chromatogram of the antimicrobial peptide 3RF.

[0033] Example 3

[0034] The critical aggregation concentration (CAC) of nanopeptides was determined by using 1-anilino-8-naphthalenesulfonate (ANS) fluorescent probe. Preparation of dye: ANS powder was dissolved in N,N-dimethylformamide (DMF) to a concentration of 40 mM, and stored in a dark and low temperature for later use. Different concentrations of antimicrobial peptide 3RF (1-256 μM) were dissolved in PB (10 mM, pH 7.4) buffer and incubated at room temperature for 12 hours. Subsequently, different concentrations of antimicrobial peptide 3RF were mixed with ANS. The changes in fluorescence intensity were monitored using an enzyme-labeled instrument at an excitation wavelength of 360 nm and an emission wavelength of 420-670 nm, with a slit width of 2 nm; Figure 3 As shown, obvious fluctuations in fluorescence intensity can be observed, which indicates that the antimicrobial peptide 3RF has a certain aggregation self-assembly ability.

[0035] Example 4

[0036] Determination of antibacterial activity of antimicrobial peptide 3RF

[0037] The minimum inhibitory concentration (MIC) of the peptides was determined by standard microbroth dilution method. Bacteria in logarithmic phase were diluted to ~2×10 5 CFU / mL. 50 μl of different concentrations of antimicrobial peptide 3RF (final concentration of 1-128 μM) and an equal volume of bacterial suspension were added to each well of a 96-well plate, and a negative control (medium only) and a positive control (bacteria and medium) were set up at the same time. The 96-well plate was then placed in a 37°C constant temperature incubator for 18 to 20 hours. The absorbance at 492 nm was measured using an ELISA reader. Two parallels were set up for each test, and these tests were repeated at least three times. The results are shown in Table 2.

[0038] Table 2 Minimum inhibitory concentration of antimicrobial peptide 3RF (μM)

[0039]

[0040] It can be seen from Table 2 that the antimicrobial peptide 3RF has excellent activity against methicillin-resistant Staphylococcus aureus MRSA, kanamycin-resistant Escherichia coli M15 and spectinomycin-resistant Pseudomonas aeruginosa 109004, with the minimum inhibitory concentration being 2-4 μM.

[0041] Example 5

[0042] Determination of hemolytic activity of antimicrobial peptide 3RF

[0043] Preparation of blood: fresh human blood was drawn, centrifuged at 3000-3500rpm for 10 minutes at 4°C, the supernatant was aspirated, phosphate buffer (PBS PH=7.4) was filtered with a 0.22μM water filter, then added to the red blood cells, the red blood cells were centrifuged and washed three times, and finally the red blood cells were resuspended in 10 times the volume of PBS. Dilution of antimicrobial peptide 3RF: PBS was added to columns 1-12 of a 96-well plate, 90μL was added to the first column, and 50μL was added to the other columns. 10μL of the dissolved nanopeptide solution was drawn and added to the first column of the 96-well plate, and diluted to the 10th column. Addition of red blood cells: the resuspended red blood cells were added to columns 1-12 of the 96-well plate, 50μL per well. 0.1% Triton X-100 was added to column 12 as a positive control (100% hemolysis), and column 11 as a negative control. The 96-well plate was placed in a 37°C incubator for 1 hour, and then the 96-well plate was centrifuged at 1000×g for 5 minutes at 4°C, and 50 μL of the supernatant from each well was transferred to a new 96-well plate. Result determination: The absorbance at 570 nm was determined using an ELISA reader. Two parallels were set for each test, and these tests were repeated at least three times.

[0044] like Figure 4 As shown, the antimicrobial peptide 3RF exhibited negligible hemolytic effect at all tested concentrations, indicating that the antimicrobial peptide 3RF has good biocompatibility.

[0045] In summary, the antimicrobial peptide 3RF has excellent antibacterial activity against methicillin-resistant Staphylococcus aureus MRSA, kanamycin-resistant Escherichia coli M15 and spectinomycin-resistant Pseudomonas aeruginosa 109004, and has almost no toxicity to human red blood cells, and has extremely high application potential.

Claims

1. A self-assembling antimicrobial peptide 3RF for resisting drug-resistant bacteria, characterized in that: It comprises a branch chain A and a branch chain B, wherein the amino acid sequence of the branch chain A is: RRRCFFF, the amino acid sequence of the branch chain B is: FFFCRRR, and the branch chain A and the branch chain B are connected via a disulfide bond formed between the thiol groups in two cysteine ​​residues.

2. The self-assembling antimicrobial peptide 3RF for resisting drug-resistant bacteria according to claim 1, wherein the molecular formula is as shown in formula (I): .

3. The self-assembling antimicrobial peptide 3RF for resisting drug-resistant bacteria according to claim 1, characterized in that: The nano self-assembly conditions are as follows: dissolving the antimicrobial peptide 3RF in a PB buffer solution with a concentration of 10 mM and a pH of 7.4, wherein the concentration of the antimicrobial peptide 3RF is 32-256 μM, incubating at room temperature for 12 hours, and self-assembling into a nanostructure.

4. The method for preparing a self-assembling antimicrobial peptide 3RF against drug-resistant bacteria according to claim 1, characterized in that: The method is as follows: two branches are designed, the sequence of branch A is: RRRCFFF, the sequence of branch B is: FFFCRRR, branch A and branch B are connected through a disulfide bond formed between thiol groups in two cysteine ​​residues, and the self-assembly of branch A and branch B is driven by cation-π interaction; branch A and branch B are synthesized separately by solid phase chemical synthesis, and then branch A and branch B are connected through a disulfide bond formed between thiol groups in two cysteine ​​residues, the polypeptide is identified by mass spectrometry and purified by reversed-phase high performance liquid chromatography to obtain the polypeptide, and then the polypeptide self-assembly morphology is observed, the antibacterial activity is determined, and the hemolytic toxicity is determined, and finally it is named antimicrobial peptide 3RF.

5. Use of the self-assembling antimicrobial peptide 3RF against drug-resistant bacteria according to claim 1 in the preparation of a drug for treating infectious diseases caused by drug-resistant bacteria, wherein the drug-resistant bacteria are methicillin-resistant Staphylococcus aureus, kanamycin-resistant Escherichia coli or spectinomycin-resistant Pseudomonas aeruginosa.

Citation Information

Patent Citations

  • Self-assembled dendritic antibacterial peptide Pal3RP, preparation method thereof, self-assembled nano-particles thereof and application of self-assembled dendritic antibacterial peptide Pal3RP and self-assembled nano-particles thereof

    CN114106106A

  • Compositions for enhancing transport of molecules into cells

    US20040265879A1